Collegium Pharmaceutical, Inc. Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities
Collegium Pharmaceutical, Inc. (COLL) reported Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities of 0 shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2026-03-31 was 6.61M shares.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-09-30 was 6.61M shares, a 0.00% change year-over-year.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for the quarter ending 2025-06-30 was 6.61M shares, a 0.00% change year-over-year.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2025 was 6.61M shares, a 0.00% change from fiscal 2024.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2024 was 6.61M shares, a 2.75% decline from fiscal 2023.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2023 was 6.79M shares.
- Collegium Pharmaceutical, Inc. incremental common shares attributable to dilutive effect of conversion of debt securities for fiscal 2021 was 4.93M shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 3 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 6 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 9 month | Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 | ||
| 2026-03-31 | 6.61M shares 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | 6.61M shares 10-K · filed 2026-02-26 | |||
| 2025-09-30 | 6.61M shares 10-Q · filed 2025-11-06 | 6.61M shares 10-Q · filed 2025-11-06 | ||
| 2025-06-30 | 6.61M shares 10-Q · filed 2026-08-06 | 6.61M shares 10-Q · filed 2026-08-06 | ||
| 2025-03-31 | 0.00 shares 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | 6.61M shares 10-K · filed 2026-02-26 | |||
| 2024-09-30 | 6.61M shares 10-Q · filed 2025-11-06 | 6.61M shares 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | 6.61M shares 10-Q · filed 2025-08-07 | 6.61M shares 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | 7.51M shares 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | 6.79M shares 10-K · filed 2026-02-26 | |||
| 2023-09-30 | 7.51M shares 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 7.51M shares 10-Q · filed 2024-08-08 | |||
| 2021-12-31 | 4.93M shares 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |